Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RL-MPV, Auto-HCT, and Nivolumab for Primary CNS Lymphoma
NCT05425654Phase 2Recruiting
- Sponsor
- National Medical Research Center for Hematology
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide, nivolumab in primary central nervous system lymphoma (PCNSL), sponsored by National Medical Research Center for Hematology. Started May 2021; status: recruiting.
02
Drugs
lenalidomidenivolumab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT05425654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05425654.